18:26 , Jun 22, 2018 |  BC Week In Review  |  Clinical News

AZ reports Phase III data for hairy cell leukemia candidate

AstraZeneca plc (LSE:AZN; NYSE:AZN) reported data from the Phase III 1053 trial in 80 patients with relapsed or refractory hairy cell leukemia who have received at least two prior therapies showing that moxetumomab pasudotox (formerly...
19:32 , Jun 15, 2018 |  BC Week In Review  |  Financial News

Autolus proposes IPO terms

Cell therapy developer Autolus Therapeutics Ltd. (London, U.K.) revealed terms for its proposed IPO on NASDAQ. In a regulatory filing June 8, the company proposed to sell 7.8 million ADSs at $15-$17, with each ADS...
13:09 , Jun 8, 2018 |  BC Extra  |  Financial News

Autolus proposes IPO terms

Cell therapy developer Autolus Therapeutics Ltd. (London, U.K.) revealed terms for its proposed IPO on NASDAQ. In a regulatory filing Friday, the company proposed to sell 7.8 million ADSs at $15-$17, with each ADS representing...
14:51 , Apr 6, 2018 |  BC Week In Review  |  Clinical News

FDA reviewing AZ's hairy cell leukemia candidate

The MedImmune LLC unit of AstraZeneca plc (LSE:AZN; NYSE:AZN) said FDA accepted and granted Priority Review to a BLA for moxetumomab pasudotox to treat hairy cell leukemia in adults who have received at least two...
16:57 , Apr 3, 2018 |  BC Extra  |  Company News

FDA reviewing AstraZeneca hairy cell leukemia therapy

The MedImmune LLC unit of AstraZeneca plc (LSE:AZN; NYSE:AZN) said FDA accepted and granted Priority Review to a BLA for moxetumomab pasudotox to treat hairy cell leukemia in adults who have received at least two...
23:26 , Mar 21, 2018 |  BioCentury  |  Finance

Seeking domestic partners

The syndicate behind TCR2 Therapeutics Inc.’s $125 million series B round includes a bevy of Chinese investors who could provide access to development and manufacturing partners in China. 6 Dimensions Capital and Curative Ventures led the...
22:26 , Jan 11, 2018 |  BC Extra  |  Company News

Pfizer's Barrett named CEO of Novartis Oncology

Novartis AG (NYSE:NVS; SIX:NOVN) hired Elizabeth Barrett as CEO of Novartis Oncology, effective Feb. 1. She succeeds Bruno Strigini, who is retiring for personal reasons (see BioCentury Extra, Dec. 15, 2017). Barrett is global president and...
02:15 , Dec 16, 2017 |  BioCentury  |  Product Development

Assessing the BCMA scene

Differences in patient populations and a dearth of clinical outcome data mean it’s too soon to declare bluebird bio Inc.’s anti-BCMA chimeric antigen receptor therapy the leader of the pack of CARs that presented clinical...
04:21 , Dec 9, 2017 |  BioCentury  |  Product Development

Multimodal meeting

This year’s clinical abstracts at the American Society of Hematology meeting hint at how newer treatment modalities -- cell therapies in cancer and gene therapies in hematology -- will branch out into new indications and...
21:36 , Sep 29, 2017 |  BC Week In Review  |  Financial News

CAR T company Autolus raises $80M series C

On Sept. 26, chimeric antigen receptor (CAR) T cell therapy company Autolus Ltd. (London, U.K.) raised $80 million in a series C round from new investors Cormorant Asset Management and Nextech Invest and existing investors...